Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Modified mrna and aav vectors: BayerRecent Research Landscape

Off-target cleavage risks and delivery inefficiencies in gene editing drive high clinical failure rates. These innovations mitigate these risks by engineering programmable endonucleases with refined PAM recognition and optimizing mRNA-LNP delivery vehicles.

What technical problems is Bayer addressing in Modified mrna and aav vectors?

Limited therapeutic payload capacity

(7)evidences

Off-target cleavage and restricted recognition sites limit therapeutic safety and utility. Enhancing specificity prevents unintended genetic mutations.

Unintended protein structural degradation

(4)evidences

Chemical instability and physical loss of potency in biologics and blood products. Preventing degradation ensures shelf-life and clinical efficacy.